Advanced age is the main risk factor for a range of human diseases. However, the fundamental mechanisms that drive aging remain largely unknown, impeding the development of interventions that delay or prevent age-related disorders and maximize the number of years without serious or chronic illnesses, referred to as healthspan. Senescent cells are known to accumulate in various tissues and organs with age and are thought to disrupt tissue structure and function by components they secrete. However, definitive evidence that senescent cells are causally implicated in aging and age-related disease has been lacking. To address the role of in vivo senescence in aging, we have generated a transgenic mouse model, termed INK-ATTAC, designed to inducibly kill pi 6'"''''^-positive senescent cells upon administration of a synthetic drug. Our preliminary data indicate that the /A/K-ATTAC transgene inducibly kills pi 6'"'"*^-positive senescent cells in the BubRI hypomorphic mouse model of premature aging, thereby delaying the onset of age-related pathologies. Based on these data we formulated the central hypothesis that cellular senescence is causally implicated in aging and that removal of senescent cells can prevent or delay age-related diseases and extend lifespan. We propose to test this hypothesis by pursuing three specific aims.
In aim 1, we will identify p16'"'"'^-positive senescent cells in mouse tissues and optimize conditions for /A//<-A7TAC-mediated killing.
In aim 2, we will employ INK-ATTACXo prevent accumulation of p16'"'"**-positive senescent cells throughout life and measure its impact on healthspan and lifespan.
In aim 3, we will induce //VK-ATTAC-mediated clearance of senescent cells from aged mice to determine whether this treatment can delay or revert age-related diseases and extend lifespan. Based on our preliminary data in the premature aging model, we expect this subproject to reveal that senescent cells contribute to age-related loss of function and disease, and that elimination of senescent cells from tissues and organs increases healthspan in the absence of overt negative side effects. The research in this application is innovative, in our opinion, because it focuses on an entirely novel approach, senescent cell clearance, as a means to counteract aging-related functional decline and prevent chronic diseases and long-term illnesses. Overall, successful completion of Subproject 1 will significantly improve our understanding of the basic mechanisms of in vivo senescence and aging, and will lay the foundation for development of drugs that slow the development of aging-associated disorders by eliminating senescent cells, thus improving healthspan and quality of life of the elderly.

Public Health Relevance

Whether and how cellular senescence is related to age-related diseases, frailty, and dysfunction is one of the major open questions in the biology of aging and clinical geriatrics. We can address this question now that we have developed a transgenic mouse model that can inducibly kill senescent cells. The proposed research is relevant as it will develop fundamental knowledge that will ultimately help reduce aging-related diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG041122-03
Application #
8665357
Study Section
Special Emphasis Panel (ZAG1-ZIJ-2)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
3
Fiscal Year
2014
Total Cost
$615,168
Indirect Cost
$203,879
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
van Deursen, Jan M (2014) The role of senescent cells in ageing. Nature 509:439-46
Campisi, Judith; Robert, Ladislas (2014) Cell senescence: role in aging and age-related diseases. Interdiscip Top Gerontol 39:45-61
Escande, Carlos; Nin, Veronica; Pirtskhalava, Tamar et al. (2014) Deleted in Breast Cancer 1 regulates cellular senescence during obesity. Aging Cell 13:951-3
Campisi, Judith (2014) Cell biology: The beginning of the end. Nature 505:35-6
Zhu, Yi; Armstrong, Jacqueline L; Tchkonia, Tamara et al. (2014) Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Nutr Metab Care 17:324-8
Stout, Michael B; Tchkonia, Tamara; Pirtskhalava, Tamar et al. (2014) Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice. Aging (Albany NY) 6:575-86
Childs, Bennett G; Baker, Darren J; Kirkland, James L et al. (2014) Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep 15:1139-53
Tchkonia, Tamara; Thomou, Thomas; Zhu, Yi et al. (2013) Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 17:644-56
Kirkland, James L (2013) Translating advances from the basic biology of aging into clinical application. Exp Gerontol 48:1-5
Baker, Darren J; Weaver, Robbyn L; van Deursen, Jan M (2013) p21 both attenuates and drives senescence and aging in BubR1 progeroid mice. Cell Rep 3:1164-74

Showing the most recent 10 out of 13 publications